The global alpha emitters market size is expected to reach USD 1,464.04 million by 2032, according to a new study by Polaris Market Research. The report “Alpha Emitters Market Share, Size, Trends, Industry Analysis Report, By Type of Radionuclide (Radium, Actinium, Lead, Bismuth, and Others); By Application; By Region; Segment Forecast, 2023- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The rapid increase in awareness regarding the potential benefits of the targeted alpha emitter and the surge in the number of patients with several types of cancers like ovarian cancer, pancreatic cancer, melanoma, and lymphoma, coupled with the rising usage of alpha therapy due to its exceptionally high cell-killing ability, are among the prominent factors influencing the global market growth.
The rapid development of new targeting strategies that deliver alpha emitters specifically to cancer cells, which can be achieved by conjugating alpha-emitting isotopes with specific targeting molecules such as antibodies, peptides, or small molecules, enabling more precise delivery of the radiation dose to cancer cells while sparing healthy tissues, has been further creating lucrative growth opportunities soon. For instance, in June 2022, Alpha Tau Medical developed ‘Alpha DaRT” and enrolled 1st patient in its feasibility study to evaluate neo-adjuvant therapy for patients who have prostate cancer.
Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/alpha-emitters-market/request-for-sample
The growing penetration of automation as an important technological development in alpha emitters, particularly in the production of radiopharmaceuticals, has been pushing the market forward. The use of automated systems for labeling molecules with alpha emitters has made the production of radiopharmaceuticals faster and more efficient, allowing for larger-scale production and lower costs, due to which patients would be able to get access to these therapies more easily or conveniently.
Furthermore, researchers worldwide are exploring the use of combination therapies that combine alpha emitters with other cancer treatments, such as chemotherapy, immunotherapy, or radiation therapy, that could potentially enhance the efficacy of cancer treatments and reduce side effects.
Alpha Emitters Market Report Highlights
Polaris Market Research has segmented the alpha emitters market report based on type of radionuclide, application, and region:
Alpha Emitters, Type of Radionuclide Outlook (Revenue - USD Million, 2019 - 2032)
Alpha Emitters, Application Outlook (Revenue - USD Million, 2019 - 2032)
Alpha Emitters, Regional Outlook (Revenue - USD Million, 2019 - 2032)
Report Attributes |
Details |
Market size value in 2023 |
USD 471.73 million |
Revenue forecast in 2032 |
USD 1,464.04 million |
CAGR |
13.4% from 2023 – 2032 |
Base year |
2022 |
Historical data |
2019– 2021 |
Forecast period |
2023 – 2032 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2032 |
Segments covered |
By Type of Radionuclide, By Application, By Region |
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
Key companies |
Bayer AG, IBA Radiopharma Solution, Actinium Pharmaceutical Inc., RadioMedix Inc., Alpha Tau Medical Ltd., Telix Pharmaceuticals Ltd., Novartis AG, Fusion Pharmaceuticals, Orano Group, Cardinal Health, The Institute of Radioelements, Nordion Inc., SHINE Medical Technologies, Global Medical Solutions, Isotopia Molecular Imaging Limited, and America Elements. |
For Specific Research Requirements |